Novartis AG (NVS)

NVS on New York Consolidated

104.25USD
28 May 2015
Change (% chg)

-- (--)
Prev Close
$104.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,298,480
52-wk High
$105.82
52-wk Low
$84.17

NVS

Chart for NVS

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.43
Market Cap(Mil.): $277,713.31
Shares Outstanding(Mil.): 2,676.99
Dividend: 2.67
Yield (%): 2.56

Financials

  NVS Industry Sector
P/E (TTM): 24.09 35.92 38.01
EPS (TTM): 4.33 -- --
ROI: 10.83 16.11 15.44
ROE: 14.69 16.90 16.48
Search Stocks

Novartis digs into health tech with bet on 'robotic pill'

LONDON - Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a “robotic pill” for complex biotech drugs that would normally have to be given by injection.

27 May 2015

Novartis digs into health tech with bet on "robotic pill"

LONDON, May 27 - Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection.

27 May 2015

BRIEF-Novartis to present new data at ASCO and EHA

* Says to present new data on 21 medicines and 11 investigational compounds at ASCO and EHA Further company coverage: (Reporting By Zurich Slot)

27 May 2015

Par does not infringe Novartis' patents for Alzheimer's patch - Fed. Circ.

- A U.S. appeals court has found that Par Pharmaceutical's copycat version of a patch for Alzheimer's disease-related dementia did not infringe two patents held by the Swiss drugmaker Novartis, helping to clear the way for regulatory approval of the generic drug.

21 May 2015

BRIEF-Novartis says lung disease drug studies show positive results

* Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

20 May 2015

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients.

07 May 2015

Rich Synageva M&A premium epitomizes appetite for orphan drugs

- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.

06 May 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.15 +0.02
Pfizer Inc. (PFE.N) $34.44 +0.14
Merck & Co., Inc. (MRK.N) $59.70 +0.24
Roche Holding Ltd. (ROG.VX) CHF279.10 -3.40
Abbott Laboratories (ABT.N) $49.26 +0.25
Sanofi SA (SASY.PA) €90.92 -1.35
AstraZeneca plc (AZN.L) 4,436.50p -55.50
GlaxoSmithKline plc (GSK.L) 1,466.00p +6.00
Eli Lilly and Co (LLY.N) $76.41 +1.51
Bristol-Myers Squibb Co (BMY.N) $69.15 +0.75

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks